However, a prospective multicenter study found that SGLT2 inhibitors might also significantly modulate the cardiac autonomic neuropathy dysfunction in type 2 diabetes mellitus patients with vasovagal syncope leading to a reduction of vasovagal syncope recurrence in these patients (Sardu et al., 2022). The gene discussed is SLC5A2; the disease is Vasovagal syncope.